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ABSTRACT: Hepatitis C virus (HCV) is a human pathogen with high
morbidity. The HCV NS3/4A protease is essential for viral replication
and is one of the top three drug targets. Several drugs targeting the
protease have been developed, but drug-resistant mutant strains
emerged. Here, we screened a library and synthesized a novel class of
small molecules based on a tryptophan derivative scaffold identified as
HCV NS3/4A protease inhibitors that are active against both wild type
and mutant form of the protease. Only the compounds with predicted
binding poses not affected by the most frequent mutations in the active
site were selected for experimental validation. The antiviral activities
were evaluated by replicon and enzymatic assays. Twenty-two
compounds were found to inhibit HCV with EC50 values ranging
between 0.64 and 63 μM with compound 22 being the most active. In
protease assays, 22 had a comparable inhibition profile for the common mutant HCV GT1b D168A and the wild-type enzyme.
However, in the same assay, the potency of the approved drug, simeprevir, decreased 5.7-fold for the mutant enzyme relative to
the wild type. The top three inhibitors were also tested against four human serine proteases and were shown to be specific to the
viral protease. The fluorescence-based cell viability assay demonstrated a sufficient therapeutic range for the top three
candidates.
■ INTRODUCTION
An estimated 170 million people around the world are infected
with hepatitis C virus (HCV). HCV is transmitted through
patient exposure to infected blood. Without treatment, chronic
HCV infection can cause serious liver disease including
cirrhosis and hepatocellular carcinoma. According to the
World Health Organization record, approximately 400 000
deaths occur annually because of HCV-related complications,
making it a serious health threat.1−3 The nonstructural proteins
of HCV play important roles in the viral production and
replication. Three viral proteins, namely, NS3/4A serine
protease, NS5A IFN resistance protein, and NS4B polymerase,
are the major drug targets for the existing antiviral
therapeutics.4−6
The NS3/4A protease is responsible for selective cleavage of
polyproteins into individual viral proteins (NS4A, NS4B,
NS5A, and NS5B).7 The first NS3/4A HCV protease
inhibitors, boceprevir and telaprevir, approved in 2011, were
prescribed to patients with genotype 1 (GT1) viral strain along
with pegylated interferon alpha (PEG-IFN∝) and ribavirin. A
second generation of orally available NS3/4 HCV protease
inhibitor simeprevir (Olysio, Sovriad) and nucleoside analogue
NS5B polymerase inhibitor sofosbuvir (Sovaldi) received FDA
approval in 2013.8,9 Between 2013 and 2016, several
noncovalent peptidomimetic protease inhibitors including
linear (asunaprevir), P1−P3 macrocyclic compounds (dano-
previr, simeprevir, and paritaprevir), and P2−P4 macrocyclic
compounds (vaniprevir and grazoprevir) were also approved in
combination with NS5A interferon resistance inhibitor and/or
NS5B polymerase inhibitor.10−17 For these inhibitors, P1, P2,
P3, and P4 correspond to the substrate amino acid side-chain
equivalents in the inhibitor that interact with the S1, S2, S3, and
S4 substrate binding pockets of the protease, respectively.
There are six well-characterized HCV genotypes (GT1−
GT6), and the P2−P4 macrocyclic compounds have broad
cross-genotype specificity.1 Although GT1 is the most studied
and targeted genotype,18 several common mutants of the HCV
protease have emerged, which include Q80K/R, R155K/Q,
A156T, and D168A/V/T/H.19,20 These mutations are in the
S2 and S4 pockets
17,20−22 and may cause drug resistance.
Several studies have shown that these single amino acid
substitutions confer the resistance to all linear, P1−P3
macrocyclic, and P2−P4 macrocyclic compounds.21−26 The
most prevalent mutants causing drug resistance to all the
current NS3/4A-targeting drugs are D168A and R155K.19
Received: August 6, 2019
Accepted: September 2, 2019
Published: October 2, 2019
Article
http://pubs.acs.org/journal/acsodfCite This: ACS Omega 2019, 4, 16999−17008
© 2019 American Chemical Society 16999 DOI: 10.1021/acsomega.9b02491
ACS Omega 2019, 4, 16999−17008
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
In this study, we chose a subpocket to reduce mutation-
related drug resistance, three-dimensional (3D) modeling,
computational docking, cell-based assays, and enzymatic assays
to identify compounds that inhibit both the wild-type NS3/4A
protease and the D168A mutant. This was achieved by
optimizing the binding efficiency to S1 and S3 pockets within
the HCV NS3/4 protease active site and avoiding the S2 and S4
pockets used by the current drugs and susceptible to
mutations. The screening, identification, synthesis, and activity
validation of compounds from the UC San Diego CDIPD
library against the GT1 wild-type virus and the HCV protease
D168A virus resulted in new promising candidates with desired
properties.
■ RESULTS AND DISCUSSION
Identification of a Druggable Binding Pocket on HCV
NS3/4A. HCV NS3/4 protease inhibitors that are approved or
in clinical trials are effective against the wild-type GT1 strain,
but mutations close to S2 and S4 pockets, in particular, R155K
and D168A17,20,21 (see Figure 1), significantly reduce the
efficacy of these drugs. The X-ray crystal structure of NS3/4A
from GT1a wt strain shows that the pocket conformation is
relatively stable in part because of the inter-side-chain
interactions between R155, D168, and R123. The side chains
of R155 and D168 provide a substrate-friendly surface for the
P2 moiety of peptidomimetic protease inhibitors.
27,28 There-
fore, mutations of either of these amino acids affect the P2−S2
interactions and drug binding.28 The X-ray crystal structures of
R155K, A156T, or D168A mutants clearly illustrate this
mechanism.27 In particular, the D168A mutation occurs
frequently in viruses that have been treated with inhibitors
that bind to S2 or an adjacent S4 patch. This mutation reduces
the efficacy of drugs such as the linear inhibitor (asunaprevir)
P1−P3 macrocyclic compounds (danoprevir, simeprevir, and
paritaprevir), and P2−P4 macrocyclic compounds (vaniprevir
and grazoprevir).11−17
Because the S2 and S4 pockets are known as multidrug
resistance sites, our goal was to discover a new class of small-
molecule inhibitors that bind to the active site of the HCV
protease but have no interactions with the S2 and S4 pockets. A
model based on high-resolution co-crystal structure of HCV
NS3/4A GT1a/GT3a protease (PDB code: 5EQR)29 was
mutated to the wild-type sequence (L132I, Q168D), converted
to fully protonated models, and optimized. The selection of
HCV NS3/4A crystal structure as the docking simulation
receptor was based on the high-resolution, well-defined active
site surrounded by secondary S1 and S3 pockets. The obtained
models were used for virtual ligand screening with the Molsoft
ICM software30,31 against the structures of 26 743 compounds
that are available at the UC San Diego Center for Discovery
and Innovation in Parasitic Diseases (CDIPD).
For each compound, the binding free energy with the active
site of HCV was estimated,31 and these docking scores were
used for ranking. The docking scores were only calculated for
compounds that interact with the catalytic triad of H57, D81,
and S139 and with the nearby residues. By setting the
threshold score at −32 (arbitrary units), we identified three
classes of candidate compounds likely to bind to the active site
of the target enzyme (Figure 1). Within these classes, related
compounds had consistent docking poses. For class A
molecules, we selected five compounds with docking scores
ranging from −38 to −32 (Table S1). These molecules contain
N-phenylsulfonamide or aminosulfonamide functional groups
that were predicted to interact with the S1, S2, and S3 pockets.
For class B molecules, two compounds with docking scores
ranging from −34 to −32 were selected (Table S2). These
compounds bind to the active site of the HCV protease in a
different orientation from the class A molecules and primarily
interact with S1, S3, and S4 pockets. They consist of phenyl
imidazolidine or phenyl triazolidin. The docking poses of
compounds from these two classes show interactions with
either the S2 pocket (class A) or the S4 pocket (class B) and are
therefore not ideal compounds for perusing biochemical and
cell-based studies using a protease with mutations in both the
S2 and S4 pockets.
The class C molecules contain a tryptophan derivative
scaffold that binds to a smaller patch compared to the class A
and class B molecules. Importantly, the 14 molecules in this
class (1−14) do not interact with the S2 and S4 pockets of
HCV protease. They primarily bind to the S1 and S3 pockets
(Figure 1) and have binding scores ranging from −32 to −38.
Within the library of 26 743 compounds, we selected five
additional compounds that were structurally similar to the
members of the class C group (15−19); however, their
Figure 1. Binding poses of compounds from class A, B, and C in the HCV GT1a NS3/4A crystal structure represented by molecular surface
colored by the side-chain types (PDB code 5EQR).29 Binding mode from class A and class B have interactions in drug resistance susceptible
subpockets S2 and S4, while class C compounds show preferred interaction with the receptor.
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Table 1. Inhibition of Viral Replication (EC50) in the HCV Replicon Assay for GT1b wt Selected 20 Compounds with the
Same Chemical Scaffold Suggested by a Docking Screena
aThe compounds are labeled from 1 to 20. For each compound, the R groups are shown along with EC50 values, median lethal concentration at
50% (LC50) for BM4-5 human liver cells, and three calculated descriptors.
bBinding score is calculated using ICM-Pro v3.8.30 cHCV replicon assay.
dCellTiter-Blue cell viability assay. eTherapeutic index is the ratio of LC50 to EC50.
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binding scores were below the −32 cutoff. These compounds
were selected for the downstream cell-based studies. In
addition, libraries of commercially available compounds were
searched for class C-related structures, docked and scored.
From this search, we found a compound with high structural
similarity and a lower binding score of −40. For our studies,
we named this compound as analogue 20 (Table 1) (Figure 2).
One important feature of this class of compounds is the
ureido group that connects the core structure and R1 group. A
bidentate bond between the two secondary amines of the
ureido group with the carbonyl oxygen of R155 backbone
(Figure 3) stabilizes the ligand−enzyme interaction. In GT1a
drug resistance mutants such as R155K and D168A, there are
no salt bridges between the R155, D168, and R123 triads; thus,
an additional backbone stabilization of R155 may be needed
for a strong binding of the inhibitor to the mutant. The
docking poses of superimposed structures of 20 compounds in
NS3/4 GT1a (Figure S1) show consistency of binding modes
among the compounds in this class. Substituted R2 and indole
groups of class C compounds are predicted to have
interactions in the S1 and S3 subpockets, the main targeted
pockets, in HCV protease active site. In addition, the H57
residue is involved in pi-stacking (3.78 Å) interactions with the
substituted aromatic rings in R1 for all the 20 inhibitors.
The 20 compounds from class C were tested in vivo for
inhibition of viral replication (GT1b wt) in BM4-5 FEO cells
and for mammalian cell cytotoxicity. The number of virus
particles was evaluated by quantifying the luciferase produced
during the virus life cycle,32 while toxicity was evaluated using
a cell viability assay. For viral replication, the 48 h EC50 of
these compounds ranged from 0.64 to 63.44 μM (Table 1),
while the 48 h cell toxicity ranged from 2.24 μM to more than
100 μM. Prior to additional biochemical studies, several key
chemical properties for each of the class C molecules were
determined. The polar surface area (PSA), the predicted
lipophilicity (clog P), and the molecular weight for each
compound (Table 1) were in agreement with the general
criteria for drug-like molecules.
The efficacy and toxicity of class C compounds were found
to be diverse with the therapeutic index, defined as the ratio of
50% lethal concentration for uninfected to 50% viral growth
inhibition concentration of infected cells, for antiviral activity
relative to cell toxicity ranging from 0.3 to 31. We were
interested in pursuing biochemical studies for compounds 1
and 12, the two candidates with the highest therapeutic index.
These compounds also had favorable properties, such as
molecular weight, water solubility PSA, and permeability
within an acceptable range for a drug-like molecule.
Design of New Compounds for Improved Binding to
HCV Protease. In compounds 1 and 12, the R2 functional
group consisted of 1-propyl-2-methyl-piperidine. On the basis
of the predicted docking poses, removal of the methyl group
was expected to improve the interaction between the catalytic
triad and the adjacent residues in the HCV protease active site.
Therefore, we designed analogues of compounds 1 and 12 that
lacked the methyl group at R2 and called them compounds 21
and 22, respectively. The binding score of 21 was unchanged
from 1 (both −38), while the binding score of 22 was slightly
better than 12 (−34 vs −33) (Table 2). The lowest energy
binding pose of compound 22 in the active site of HCV NS3/
4A is shown in Figure 4.
Synthesis of Compounds 21 and 22. As highlighted in
Scheme 1, the tryptophan-derived HCV NS3/4 protease
inhibitors, 21 and 22, were synthesized starting from 3-
(piperidine-1-yl)propan-1-amine (23), which could be ac-
cessed in two steps from commercially available N-
(bromopropyl)phtalimide and piperidine, and N-Boc-pro-
tected L-tryptophan (24). Thus, the HBTU-mediated coupling
of 25 and 24, followed by N-Boc deprotection and
carbamoylation reaction with the appropriate isocyanate,
provided the desired compounds, 21 and 22. These test
compounds were characterized by 1H NMR, 13C NMR, and
HRMS. In addition, the experimental pKa values, lipophilicity
(clog P), and log D7.4 of 22 were determined via
potentiometric titrations using a Sirius T3 instrument.
Compounds 21 and 22, as well as the 20 compounds from
the primary screen, were then tested in cell-based assays to
evaluate activity against HCV and toxicity to the host cells
(Table 2).
Evaluation of Compounds in Viral Replication Assays
and HCV Protease Activity Assays. Compounds 21 and 22
were evaluated in the HCV replicon assay and for cytotoxicity
using BM4-5 FEO cells. Compound 21 had slightly weaker
antiviral activity than 1 but lower cytotoxicity; therefore, the
therapeutic index was unchanged for these two analogues. The
IC50 value for compound 22 was 2-fold more potent than the
related compound 12 and the cytotoxicity was unchanged.
Therefore, the therapeutic index for 22 improved 2-fold over
12 from 30.6 to 73.4.
In order to validate that this group of molecules elicit their
cellular effects via inhibition of the viral protease, we incubated
compounds 1, 12, and 22 with recombinant NS3/4A protease
Figure 2. Common structure of class C that contains a tryptophan
derivative scaffold identified as HCV NS3/4A protease inhibitors.
Figure 3. Structural modeling of compound 12 in the HCV NS3/4A
active site. The binding mode of 12 (light yellow) in the HCV GT1a
NS3/4A crystal structure is represented by multicolor skin (PDB code
5EQR).29 Compound 12 is occupied in S1 and S3 pockets and forms
hydrogen bond interactions (dashed green) with R155 and I132
(pink), and hydrogen bonding interactions are shown as dashed green
and orange lines. Pi-stacking interaction (dashed red) between the
isopropylphenyl group of 12 and H57 (pink) with a distance of 3.78
Å.
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GT1b and an inhibitor-resistant mutant containing a D168A
mutation. D168 is located in the S2 and S4 subpockets, and
mutations in these subpockets can cause significant resistance
to the inhibitors, resulting in decreased activity of peptidomi-
metic inhibitors.3,33,34 The enzyme activity was evaluated using
a fluorogenic peptide substrate, Ac-Glu-Glu-Val-Val-Ala-Cys-
AMC, that has previously been described as a HCV protease
substrate.35 No enzyme assays were performed with compound
21 because it showed no improvement in antiviral activity or
selectivity when compared to the parent molecule, 1. As a
control, potency was evaluated with an approved HCV
protease inhibitor, simeprevir.
The HCV protease was incubated with 0.625−40 μM of
compounds 1, 12, and 22 and the IC50 values were calculated.
These studies show that the wt protease activity is directly
Table 2. Inhibition of Viral Replication (EC50) in the HCV Replicon Assay for GT1b wt by Two Synthesized Compounds (21,
22)a
aFor each compound, the R groups are shown along with EC50 values, median lethal dose (LC50) for BM4-5 human liver cells, and three calculated
descriptors. bBinding score calculated using ICM-Pro v3.8.30 cHCV replicon assay. dCellTiter-Blue cell viability assay. eTherapeutic index is the
ratio of LC50 to EC50.
fExperimental log P.
Figure 4. Structural modeling of compound 22 in HCV NS3/4A
active site. Docking pose of compound 22 in the HCV GT1a NS3/4A
crystal structure represented by molecular surface colored by the side
chain types (PDB code 5EQR).29
Scheme 1. Synthesis of 21 and 22
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inhibited by compounds derived from the tryptophan scaffold.
The potency of compound 22 was lower than simeprevir (IC50
4.60 μM vs 0.043 μM) (Table 3); however, when inhibition
was evaluated using the D168A mutant, the potency of
simeprevir decreased by 5.7-fold, while no significant reduction
of potency was observed for compound 22 (Figure 5).
Likewise, compounds 1 and 12 that showed high efficiency and
acceptable toxicity profile from the HCV replicon assay were
assayed with wt and mutant HCV protease and found to have
no significant change in potency. Therefore, our initial
prediction that these tryptophan-containing inhibitors do not
interact with the S2 and S4 subpockets is likely to be correct.
Other HCV protease inhibitors, such as glecaprevir,
paritaprevir, and grazoprevir, have been shown to have 4-fold
to 154-fold reduced potency in cell-based assays when
comparing the wild-type viruses with viruses that have a
mutation at D168.36
To determine the HCV NS3/4A selectivity of compounds 1,
12, and 22, we assayed these analogues with trypsin, elastase,
and chymotrypsin at the HCV IC50 concentrations. In
addition, we tested these compounds for inhibition against
the fungal serine protease, proteinase K that is structurally
related to several mammalian serine proteases such as the
proprotein convertases.37 Using a concentration of 40 nM for
each enzyme, we found that 13.08 and 14.68, 4.60 μM of 1, 12,
and 22, respectively, did not decrease the activity of trypsin,
elastase, chymotrypsin, and proteinase K significantly, while, at
this concentration, these three compounds decreased HCV
NS3/4A activity by about 50% (Figure 6). Taken together,
these data indicate that compounds with the tryptophan
scaffold derivative were selective from the viral protease over
other serine proteases.
■ CONCLUSIONS
In this study, we identified and synthesized a new class of
inhibitors of HCV protease that shows similar potency for the
wild-type and D168A mutant enzymes. The inhibitory activity
against the mutant was achieved by targeting subpockets not
affected by the D168A mutation. The compounds were
dissimilar to the common HCV protease inhibitors that
contained groups mimicking P1, P2, P3, and P4 substrate side
chains. In particular, 22 had an EC50 of 0.64 μM in a viral
replication assay and an LC50 of 47 μM for mammalian cells,
resulting in an overall therapeutic index of 73.4. This
compound directly inhibited the protease with IC50 = 4.60
μM and no significant reduction if potency occurred when
assayed with the D168A mutant. Three of the top compounds
were tested against a panel of four nonviral serine proteases
and no significant inhibition was noted. The new NS3/4A
protease inhibitors are promising development candidates for
treatment of emerging drug-resistant HCV strains.
Table 3. NS3/4A Inhibitory Assay of Compounds 1, 12, and
22a
compound
IC50 (μM)
GT1b wt
IC50 (μM) GT1b
D168A
IC50_D168A/IC50_wt
ratio
1 14.68 ± 1.23 11.37 ± 0.45 0.8
12 13.08 ± 2.77 11.45 ± 0.55 0.9
22 4.60 ± 1.26 5.98 ± 0.43 1.4
simeprevir 0.043 ± 0.79 0.247 ± 0.39 5.7
aThe identified compounds inhibit both the wild type and the D168A
mutant form of protease at similar IC50 values.
Figure 5. HCV NS3/4A protease inhibition assay. Dose response curve of 22 with HCV protease GT1b wt (A) and D168A mutant (B) derived
from the relative fluorescence absorption that represents the concentration of the cleavage products of fluorogenic peptide substrate (Ac-Glu-Glu-
Val-Val-Ala-Cys-AMC) at 60 μM by GT1b wt protease or by the D168A mutant in the presence of 22 at inhibitor concentrations between 0.625
and 40 μM; the errors calculated from three measurements at each concentration.
Figure 6. HCV protease selectivity of top three compounds against
four human serine proteases. Counter-screening on of 1, 12, and 22 at
13.08, 14.68, 4.60 μM, respectively, to 40 nM concentration of HCV
NS3/4A, trypsin, elastase, chymotrypsin, and proteinase K shows high
HCV-NS3-specificity of 1, 12, and 22 inhibitors.
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■ EXPERIMENTAL SECTION
All solvents were of reagent grade. All reagents were purchased
from Aldrich, Enamine, or Fisher Scientific and used as
received. Thin-layer chromatography (TLC) was performed
with 0.25 mm E. Merck precoated silica gel plates. Silica gel
column chromatography was performed with silica gel 60
(particle size 0.040−0.062 mm) supplied by Silicycle and
Sorbent Technologies. TLC spots were detected by viewing
under a UV light (254 nm). Proton (1H) and carbon (13C)
NMR spectra were recorded on a 600 MHz Bruker AVANCE
III spectrometer. Chemical shifts were reported relative to the
residual solvent’s peak. High-resolution mass spectra were
measured using Thermo LCQdeca-MS. Unless otherwise
stated, all final compounds were found to be >95% pure as
determined by HPLC/MS and NMR.
3-(Piperidine-1-yl)propan-1-amine (23). To a stirring
solution of piperidine (1 g, 11.74 mmol) in acetone (11 mL),
N-(bromopropyl)phthalimide (0.739 g, 2.935 mmol) was
added. The mixture was heated at 56 °C and stirred for 18
h.38 Then, the solvent was evaporated obtaining a dark yellow
powder, which was redissolved in ethyl acetate, washed with 2
M of K2CO3, and extracted with 2 M of HCl. The aqueous
layer was adjusted to pH 11 and re-extracted with dichloro-
methane (DCM). The solvent was evaporated, and the
resulting dark yellow brown crude was added with 6 M HCl
(40 mL) and then heated to reflux for 18 h. The reaction
mixture was then washed with DCM, added with NaOH to
adjust the pH to 12, and extracted again with DCM. The
organic layer was dried over sodium sulfate, filtered, and
evaporated under reduced pressure to obtain the desired
product as a brown solid and evaporated to get a brown crude
of intermediate 24 in 74% yield (0.309 g). 1H NMR (CDCl3):
δ (ppm) 2.752 (t, J = 6.9 Hz, 2H), 2.363 (m, 6H), 1.663 (m,
2H), 1.660 (m, 6H), 1.451 (m, NH2). MS for C8H19N2 [M +
H+], 143.15.
tert-Butyl (3-(1H-Indol-3-yl)-1-oxo-1-((3-(piperidin-1-
yl)propyl)amino)propan-2-yl)carbamate (24). To a sol-
ution of Nα-(tert-butoxycarbonyl)-L-tryptophan (0.643 g,
2.112 mmol) in anhydrous dimethylformamide (DMF, 8
mL), HBTU (1.602 g, 4.225 mmol) and Et3N (1.068 g, 10.56
mmol) were added, followed by a dropwise addition of 24
(0.309 g, 2.176 mmol) in DMF (1.6 mL). The reaction
mixture was stirred at room temperature for 22 h. During the
reaction, the solution color changed from yellow to dark green
in 2 h. The completion of the reaction was checked by TLC
using 10% MeOH in dimethyl sulfoxide (DMSO) as the
solute. The reaction was quenched by addition of saturated
aqueous solution of NaHCO3, which caused the mixture to
turn yellow with white cloudy precipitates. The aqueous layer
was extracted with ethyl acetate. The organic layer was dried
over sodium sulfate, filtered, and evaporated under reduced
pressure. Purification via silica gel column chromatography
(15% MeOH in DCM) furnished the title compound in 26%
yield (0.240 g). 1H NMR (CDCl3): δ (ppm) 8.785 (s, 1H),
7.635 (d, J = 6.6 Hz, 1H), 7.368 (d, J = 6.6 Hz, 1H), 7.289 (s,
1H), 7.181 (t, J = 7.8 Hz, 1H), 7.112 (t, J = 7.2 Hz, 1H), 7.082
(s, 1H), 4.410 (t, J = 3.6 Hz, 1H), 3.332 (d, J = 13.2 Hz, 2H),
3.186 (t, J = 6.0 Hz, 2H), 2.245 (m, 4H), 2.193 (t, J = 6.0 Hz,
2H), 1.510 (m, 4H), 1.453 (s, 9H), 1.402 (m, 2H). 13C NMR
(CDCl3): δ (ppm) 171.697, 155.378, 136.217, 127.648,
123.339, 122.066, 119.514, 119.042, 111.232, 110.551,
79.830, 57.225, 55.454, 54.148, 38.980, 28.906, 28.885,
25.130, 24.206, 23.755. MS for C24H36N4O3 [M + H
+], 429.29.
2-Amino-3-(1H-indol-3-yl)-N-(3-(piperidin-1-yl)-
propyl)propanamide (25). To a solution of 25 (50 mg, 0.17
mmol) in DCM (1.6 mL), trifluoroacetyl (0.35 mL) was added
dropwise and the resulting mixture was stirred for 1 h.
Evaporation of volatiles under reduced pressure followed by
trituration in diethyl ether furnished the desired compounds in
88% yield (51 mg, 0.15 mmol) as a brown powder. 1H NMR
(MeOD): δ (ppm), 8.484 (s, NH2), 7.641 (d, J = 7.8 Hz, 1H),
7.413 (d, J = 7.4 Hz, 1H), 7.263 (s, 1H), 7.168 (t, J = 7.2 Hz,
1H), 7.091 (t, J = 7.2 Hz, 1H), 4.127 (t, J = 4.2 Hz, 1H), 3.334
(d, J = 12 Hz, 4H), 3.209 (dq, J = 6.6, 23.4 Hz, 2H), 2.687 (m,
4H) 1.881 (m, 2H), 1.747 (m, 2H), 1.488 (m, 4H), 13C NMR
(MeOD): δ (ppm) 169.233, 136.632, 127.073, 124.126,
121.485, 118.886, 117.888, 111.262, 106.881, 53.866, 52.875,
52.684, 36.036, 27.186, 23.372, 22.759, 21.202 MS for
C24H36N4O3 [M + H
+], 329.23.
2-(3-(3-Bromophenyl)ureido)-3-(1H-indol-3-yl)-N-(3-
(piperidin-1-yl)propyl)propenamide (21). To a solution of
26 (50 mg, 0.1166 mmol) in DMF (1.17 mL) and the solution
was added by 3-bromophenyl isocyanate (20.98 mg, 0.106
mmol). The reaction was started by adding the catalyst Et3N
(32.4 mg, 0.318 mmol), followed by stirring for 3 h, and then
the solution turned yellow. The reaction was quenched by
adding water (12 mL), extracted by ethyl acetate (4 × 15 mL),
and washed by water (15 mL). The organic layer was purified
by column chromatography (10−15% MeOH in DCM). The
solvent was evaporated to obtain the remaining powder of 6 at
a yield of 79% (44 mg, 0.084 mmol). 1H NMR (CDCl3): δ
(ppm), 8.498 (s, NH), 8.235 (s, NH), 7.607 (d, J = 7.8 Hz,
1H), 7.561 (s, 1H), 7.290 (m, 1H), 7.198 (d, J = 7.2 Hz, 1H),
7.101 (m, 5H), 6.976 (s, NH), 4.656 (d, J = 6.6 Hz, 1H), 3.207
(m, 4H), 2.228 (m, 2H), 2.144 (m, 2H), 1.497 (m, 4H), 1.395
(p, J = 6 Hz, 4H) 1.292 (m, 2H). 13C NMR (CDCl3): δ
(ppm), 173.145, 155.411, 140.939, 136.149, 130.102, 127.498,
125.092, 125.061, 123.505, 122.450, 122.021, 121.799,
119.472, 118.724, 117.460, 111.277, 110.411, 57.546, 55.300,
54.324, 40.017, 29.812, 25.865, 24.165. MS for C26H32BrN5O2
[M + H+], 526.18.
3-(1H-Indol-3-yl)-2-(3-(4-isopropylphenyl)ureido)-N-
(3-(piperidin-1-yl)propyl)propenamide (22). To a sol-
ution of 26 (51 mg, 0.1189 mmol) in DMF (1.2 mL), 4-
isopropylphenyl isocyanate (17.4 mg, 0.108 mmol) was added,
followed by the addition of a catalytic amount of Et3N (32.8
mg, 0.324 mmol). The reaction mixture was stirred for 3 h at
room temperature, which caused the solution to turn yellow.
The reaction was quenched by adding water (12 mL) and
extracted with ethyl acetate (4 × 15 mL). The combined
organic layers were then washed with water (15 mL), dried
over sodium sulfate, filtered, and evaporated under reduced
pressure. Purification via silica gel column chromatography
(15% MeOH in DCM) furnished the title compound in 66%
yield (35 mg, 0.070 mmol). 1H NMR (CDCl3): δ (ppm),
9.071 (s, NH), 8.311 (s, NH), 7.898 (s, NH), 7.635 (d, J = 12
Hz, 1H), 7.290 (m, 3H), 7.103 (t, J = 7.2 Hz, 1H), 7.036 (m,
4H), 6.960 (s, NH), 3.244 (s, 2H), 3.116 (d, J = 27 Hz, 2H),
2.825 (t, J = 6.6 Hz, 1H), 2.217 (m, 1H), 2.128 (m, 4H), 1.466
(m, 4H), 1.364 (d, J = 9 Hz, 4H), 1.291 (s, 2H), 1.214 (d, J =
6.6 Hz, 6H), 13C NMR (CDCl3): δ (ppm) 173.287, 156.011,
142.890, 137.097, 136.162, 127.616, 126.690, 123.636,
121.781, 119.664, 119.245, 118.900, 118.866, 111.243,
110.503, 57.079, 55.240, 54.155, 39.333, 33.456, 29.765,
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29.512, 25.561, 24.521, 24.171. MS for C29H39N5O2 [M + H
+],
490.32.
Replicon Construct. The BM4-5 replicon is a subgenomic
HCV GT1b replicon that contains adaptive mutation of serine
in the NS5A region.32,39 The firefly luciferase gene was added
into the BM4-5 replicon to generate BM4-5 FEO replicon. The
construction procedures have been previously described.40
Luciferase Antiviral Efficacy and Cell Viability Assays.
The BM4-5 FEO replicon of approximately 10 000 cells in 100
μL of medium was seeded into 96-well plates and incubated for
6 h for attachment. Then, the compounds were added to the
wells in a specific concentration and incubated for 48 h. The
luciferase assay (Bright-Glo; Promega) was carried out
according to the manufacturer’s instructions. The luciferase
activity was determined using a microplate luminometer
(Veritas microplate luminometer; Turner Biosystems). For
cell viability assays, BM4-5 FEO at the density of 10 000 cells
in 100 μL medium was incubated at 37 °C for 6 h for
attachment, and then the compounds were added and
incubated for another 48 h. The number of living cells was
measured by Cell Titer-blue assay (Promega). The fluo-
rescence absorption (560Ex/590Em) for a 96-well plate was read
by Benchmark Scientific MR9600. The activity and toxicity of
each compound were measured by at least six different
concentrations in triplicate.
Plasmid Construction and Purification of HCV NS3/A
Protein. The drug-resistant mutant D168A was generated by
mutagenesis using NS3-containing recombinant plasmid
(pETDuet-1 Hepatis C Virus NS3/4A, a gift from Michael
Johnson, Addgene plasmid #16196) as a template. The single
mutation of aspartic acid (D) to alanine (A) was introduced by
mutagenesis at position 168 using specific primers (forward:
5′-GTTGCCAAAGCCGTTGCTTTCGTTCCGGTGGAA-
3 ′ and r eve r s e : 5 ′ -TTCCACCGGAACGAAAG-
CAACGGCTTTGGCAAC-3′). The overexpression and puri-
fication were preformed following the method previously
described.41 Rosetta 2(DE3) cells (Novagen) containing the
modified recombinant plasmid with a histidine tag were grown
in a lysogeny broth medium. The overexpression was
introduced by addition of isopropyl β-D-1-thiogalactopyrano-
side to the final concentration of 0.5 mM and the bacteria were
incubated at room temperature for 16 h. The cell pellet was
lysed by sonication in buffer A [50 mM HEPES (pH 7.6), 500
mM NaCl, 20 mM imidazole, 5 mM β-mercaptoethanol (β-
MCE), 0.2% Triton X-100, 15% glycerol, and protease
inhibitor cocktail (Sigma-Aldrich)]. The solution was passed
through an Ni-NTA column and washed by buffer B (50 mM
HEPES, pH 7.6, 500 mM NaCl, 50 mM imidazole, 5 mM β-
MCE, 0.2% Triton X-100, and 15% glycerol). The His-tag-
fused protein was eluted by buffer C (50 mM HEPES, pH 7.6,
500 mM NaCl, 500 mM imidazole, 5 mM β-MCE, 0.2%
Triton X-100, and 15% glycerol), followed by dialysis using
buffer (50 mM HEPES, pH 7.6, and 500 mM NaCl). Purified
NS3/4A protein was concentrated and buffer-exchanged into
buffer D (50 mM HEPES, pH 7.6, 500 mM NaCl, 5 mM β-
MCE, 0.2% Triton X-100, and 50% glycerol) using a protein
concentrator 10k (Amicon)
HCV NS3/4A Enzymatic Inhibition Assay. The activities
of two proteases (recombinant HCV NS3/4A GT1b wt and
full-length HCV NS3/4A GT1b D168A) were measured using
a fluorogenic substrate, Ac-Glu-Glu-Val-Val-Ala-Cys-AMC
(Sigma-Aldrich), where AMC corresponds to 7-amino-4-
methylcourmarin. Assays were performed in 50 mM HEPES,
pH 7.4, 15 mM NaCl, 0.01% Triton X-100, and 10 mM
dithiothreitol in a black 384-well microplate (BD Falcon). The
final concentrations of the enzyme, substrate, and DMSO were
40 nM, 60 μM, and 2.5%, respectively, in a total volume of 30
μL. Fluorescence was monitored at excitation and emission
wavelengths of 360 and 460 nm, respectively, in a Synergy
HTX Multi-Mode Microplate Reader (BioTek). Data were
visualized using Gen5 Software (BioTek). The activity of the
enzyme was calculated from the change in relative fluorescence
units over time. For inhibition assays, compounds were
preincubated with the enzyme for 240 min prior to adding
the enzyme/inhibitor mixture to the substrate. All assays were
performed in triplicate wells.
Counter-Screening Assay. Counter-screening assays were
performed with 40 nM bovine trypsin (Sigma), pig pancreatic
elastase (Sigma), human chymotrypsin, and proteinase K, and
60 μM of the appropriate fluorogenic substrates for trypsin,
elastase, chymotrypsin, and proteinase K are Boc-Leu-Arg-Arg-
AMC (trypsin), Me-Arg-Arg-Pro-Val-AMC (elastase), and
Suc-Arg-Arg-Pro-Phe-AMC (chymotrypsin and proteinase
K). Assays were performed in 50 mM HEPES, pH 7.4, 15
mM NaCl, and 0.01% Triton X-100 in black 96-well
microplates (BD Falcon) at a final volume of 50 μL. The
final concentration of DMSO in each well was 2.5%.
Fluorescence was measured as outlined above.
Computational Modeling. Docking screening was
performed by docking an in-house library of approximately
27 000 small molecules and ranked based on their docking
scores, which represent Gibbs free energy.30 The algorithm for
conformational sampling 3D structures of ligands and pockets
is generated randomly by biased probability Monte Carlo.31 All
scoring functions and pharmacokinetic property predictions
were performed by the method implemented in ICM-Pro v3.8.
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Lavanchy, D.; Laźaro, P.; Leleu, H.; Lesi, O.; Lesmana, L. A.; Li, M.;
Liakina, V.; Lim, Y.-S.; Luksic, B.; Mahomed, A.; Maimets, M.;
Makara, M.; Malu, A. O.; Marinho, R. T.; Marotta, P.; Mauss, S.;
Memon, M. S.; Correa, M. C. M.; Mendez-Sanchez, N.; Merat, S.;
Metwally, A. M.; Mohamed, R.; Moreno, C.; Mourad, F. H.;
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Deveau, L. M.; Silver, C.; Cao, H.; Newton, A.; Petropoulos, C. J.;
Huang, W.; Schiffer, C. A. The molecular basis of drug resistance
against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog.
2012, 8, No. e1002832.
(20) Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in
patients with hepatitis C virus infection. Gastroenterology 2010, 138,
447−462.
(21) Vermehren, J.; Sarrazin, C. The role of resistance in HCV
treatment. Best Pract. Res. Clin. Gastroenterol. 2012, 26, 487−503.
(22) Belfrage, A. K.; Abdurakhmanov, E.; Åkerblom, E.; Brandt, P.;
Alogheli, H.; Neyts, J.; Danielson, U. H.; Sandström, A. Pan-NS3
protease inhibitors of hepatitis C virus based on an R(3)-elongated
pyrazinone scaffold. Eur. J. Med. Chem. 2018, 148, 453−464.
(23) Lin, C.; Gates, C. A.; Rao, B. G.; Brennan, D. L.; Fulghum, J.
R.; Luong, Y.-P.; Frantz, J. D.; Lin, K.; Ma, S.; Wei, Y.-Y.; Perni, R. B.;
Kwong, A. D. In vitro studies of cross-resistance mutations against
two hepatitis C virus serine protease inhibitors, VX-950 and BILN
2061. J. Biol. Chem. 2005, 280, 36784−36791.
(24) Kurt Yilmaz, N.; Swanstrom, R.; Schiffer, C. A. Improving Viral
Protease Inhibitors to Counter Drug Resistance. Trends Microbiol.
2016, 24, 547−557.
(25) Cubero, M.; Esteban, J. I.; Otero, T.; Sauleda, S.; Bes, M.;
Esteban, R.; Guardia, J.; Quer, J. Naturally occurring NS3-protease-
inhibitor resistant mutant A156T in the liver of an untreated chronic
hepatitis C patient. Virology 2008, 370, 237−245.
(26) Romano, K. P.; Ali, A.; Aydin, C.; Soumana, D.; Özen, A.;
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